Valneva's Declaration of Shares and Voting Rights Overview
VALNEVA, a prominent company in the biopharmaceutical industry, recently announced significant updates regarding its shares and voting rights. As a company traded on Euronext Paris, Valneva is committed to transparency and clarity for its stakeholders, which this declaration exemplifies.
Company and Market Information
The registered office of VALNEVA is located at 6 rue Alain Bombard, 44800 Saint-Herblain, France. It operates within the regulated market of Euronext Paris, specifically in Compartment B. This positioning allows Valneva to maintain a robust framework for its financial operations while providing essential information to its investors.
Key Details of the Declaration
The latest declaration was made on May 7, providing insights into the number of shares making up the company's capital, the total voting rights, and the changes that have occurred alongside these figures. Notably, as of the declaration date, Valneva comprises 167,271,524 ordinary shares, each with a par value of €0.15.
Total Number of Voting Rights
The company reported a total of 183,160,262 voting rights, including any suspended rights. This total is crucial as it forms the basis for various corporate governance considerations and decisions made by shareholders.
Description of Changes in Shares
One of the most significant aspects of this declaration is the issuance of new ordinary shares. Specifically, Valneva has included details about double voting rights granted on 784 ordinary shares and has conducted a capital increase allowing for 4,750,000 new ordinary shares to be issued without preferential subscription rights. This strategic move demonstrates Valneva's growth ambitions and commitment to enhancing shareholder value.
Implications for Investors and Stakeholders
Understanding these updates is vital for current and prospective investors. Increased shares and voting rights can lead to greater representation and influence in corporate governance decisions, making it clear that Valneva is focused on expanding its operational capacity and reputation within the industry.
Shareholder Engagement
With a total of 183,035,940 voting rights excluding suspended rights, Valneva is positioning itself as a participative entity where shareholders have a real voice. Stakeholder engagement is highly valued, and this latest declaration reinforces the company's strategy to ensure active participation in decision-making processes.
Looking Ahead for Valneva
As Valneva continues to innovate and expand its offerings in the biopharmaceutical sector, staying informed about share and voting rights becomes increasingly important. The recent declaration marks just one component of the company’s ongoing communications with investors, illustrating transparency and responsiveness to market dynamics.
In the coming months, stakeholders should watch for further updates from Valneva related to share performance and governance practices, helping to determine the trajectory of the company's strategies and market positioning.
Frequently Asked Questions
What was the total number of ordinary shares reported by Valneva?
Valneva reported a total of 167,271,524 ordinary shares as part of its declaration.
When was the latest declaration of shares made?
The latest declaration was made on May 7, providing insights into the company’s share structure.
What changes occurred alongside the declaration?
The declaration detailed a capital increase issuing 4,750,000 new ordinary shares and the granting of double voting rights on certain shares.
How many voting rights does Valneva have?
The total number of voting rights reported by Valneva is 183,160,262, including suspended rights.
Why is this declaration important for investors?
This declaration is crucial as it informs investors of their rights and the company’s financial structure, enabling better investment decisions.
